Pricing Log in Create free account

Editas Medicine, Inc. (EDIT) vs ARS Pharmaceuticals, Inc. (SPRY)

Editas Medicine, Inc. and ARS Pharmaceuticals, Inc. are both Biotechnology companies. Editas Medicine, Inc. and ARS Pharmaceuticals, Inc. are of similar size ($445.4M and $420.7M). Editas Medicine, Inc. grew revenue faster over the last twelve months: 20.8% against 4.08%. Editas Medicine, Inc. has the higher net margin (−157.3% vs −184.3%) and the higher return on invested capital (0.00% vs −335.7%). Across the 17 metrics below, Editas Medicine, Inc. leads on 13 and ARS Pharmaceuticals, Inc. on 4.

Valuation

Metric EDIT SPRY Biotechnology median
P/E n/m n/m 8.56
P/S 6.98 3.58 10.17
P/B 3.12 33.50 2.34
Price to free cash flow n/m n/m 20.42
EV/EBITDA n/m n/m 0.69
EV/Sales 3.17 3.83 9.64
Earnings yield (27.27%) (51.66%) (29.41%)
Free cash flow yield (36.66%) (50.61%) (23.50%)

Profitability

Metric EDIT SPRY Biotechnology median
Gross margin 100.00% 71.37% 65.16%
Operating margin (161.39%) (184.96%) 0.00%
Net margin (157.32%) (184.26%) 0.00%
Free cash flow margin (255.88%) (167.97%) 0.00%
Return on equity (118.82%) (210.37%) (56.66%)
Return on assets (33.02%) (76.54%) (49.22%)
Return on invested capital 0.00% (335.65%) 0.00%

Growth

Metric EDIT SPRY Biotechnology median
Revenue growth (TTM) 20.83% 4.08% 5.64%
EPS growth (last fiscal year) 37.50% (2,275.00%) 30.08%
Revenue growth, 5-year CAGR (14.89%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric EDIT SPRY Biotechnology median
Debt to equity 0.00 13.72 0.00
Current ratio 3.19 3.48 4.72
Net debt to EBITDA 0.94 0.42 0.96

Dividend

Metric EDIT SPRY Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric EDIT SPRY Biotechnology median
Market cap 445.38m 420.66m 151.40m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack